SCHEMBL6520038

SCHEMBL6520038

COc1ccc(-c2nc3ccc(-c4cccc(CO)c4)cn3c2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.47
SLC2A1 P11166 6/20 0.45
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
CYP2C9 P11712 1/20 0.44
NR4A2 P43354 1/20 0.44
KCNH2 Q12809 1/20 0.44
FYN P06241 2/20 0.43
ATM Q13315 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MTNR1B P49286 3/20 0.40
MTNR1A P48039 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523662 0.90 CYP2C9 (0.48) NR1H4SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL6517372 0.87 CYP2C9 (0.41) NR1H4SLC2A1CYP11B1CYP11B2CYP2C9
SCHEMBL6525530 0.86 CYP2C9 (0.60) NR1H4SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL6523594 0.81 CYP2C9 (0.48) NR1H4SLC2A1CYP2C9NR4A2KCNH2
SCHEMBL3409155 0.81 CYP11B1 (0.49) NR1H4SLC2A1CYP11B1CYP11B2NR4A2
SCHEMBL3429663 0.79 NR1H4 (0.53) NR1H4CYP2C9NR4A2KCNH2FYN
SCHEMBL16208185 0.79 CYP2C9 (0.46) NR1H4SLC2A1CYP2C9NR4A2KCNH2
Hydrochloric Acid SCHEMBL6521449 0.78 NR1H4 (0.52) NR1H4CYP2C9NR4A2KCNH2FYN
SCHEMBL6523033 0.78 CYP11B1 (0.44) NR1H4SLC2A1CYP11B1CYP11B2ATM
SCHEMBL6521013 0.78 CYP2C9 (0.42) NR1H4SLC2A1CYP11B1CYP11B2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP claimed
US-8507520-B2 Polysubstituted 2-aryl-6-phenylimidazo[1,2-A]pyridine derivatives, and preparation and therapeutic use thereof SANOFI (FR) 2013-08-13 US claimed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN NR1H4 393/4885SLC2A1 986/4885CYP11B1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.